| scholarly article | Q13442814 |
| P2093 | author name string | Fabio Coppedè | |
| P2860 | cites work | Importance of low-range CAG expansion and CAA interruption in SCA2 Parkinsonism | Q46960409 |
| The ubiquitin pathway in Parkinson's disease | Q48015939 | ||
| Segregation of a missense mutation in the microtubule-associated protein tau gene with familial frontotemporal dementia and parkinsonism | Q48395727 | ||
| Levels of alpha-synuclein mRNA in sporadic Parkinson disease patients | Q48489167 | ||
| DNA methylation of Alzheimer disease and tauopathy-related genes in postmortem brain | Q48521070 | ||
| SPG11 spastic paraplegia. A new cause of juvenile parkinsonism | Q48739111 | ||
| Different methylation of the TNF-alpha promoter in cortex and substantia nigra: Implications for selective neuronal vulnerability | Q48875058 | ||
| A two-stage meta-analysis identifies several new loci for Parkinson's disease | Q21144948 | ||
| Genetic etiology of Parkinson disease associated with mutations in the SNCA, PARK2, PINK1, PARK7, and LRRK2 genes: a mutation update | Q22252904 | ||
| Pathogenic LRRK2 negatively regulates microRNA-mediated translational repression | Q24293587 | ||
| Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity | Q24301946 | ||
| Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism | Q24309753 | ||
| Aging-associated alteration of subtelomeric methylation in Parkinson's disease. | Q53390945 | ||
| Genetic variability in the SNCA gene influences α-synuclein levels in the blood and brain | Q56637599 | ||
| Collaborative Analysis of α-Synuclein Gene Promoter Variability and Parkinson Disease | Q57977634 | ||
| Novel mutations in SPG11 cause hereditary spastic paraplegia associated with early-onset levodopa-responsive Parkinsonism | Q59153436 | ||
| MicroRNA and proteome expression profiling in early-symptomatic α-synuclein(A30P)-transgenic mice | Q82775800 | ||
| HDAC6 regulates aggresome-autophagy degradation pathway of α-synuclein in response to MPP+-induced stress | Q83206996 | ||
| Increased incidence of Parkinson disease among relatives of patients with Gaucher disease | Q83228051 | ||
| Accumulation of histone deacetylase 6, an aggresome-related protein, is specific to Lewy bodies and glial cytoplasmic inclusions | Q83339692 | ||
| MicroRNAs in Parkinson's disease | Q83371481 | ||
| Identification of blood microRNAs associated to Parkinsonĭs disease | Q83372764 | ||
| Study of methylation levels of parkin gene promoter in Parkinson's disease patients | Q84333501 | ||
| Global DNA hypomethylation and DNA hypermethylation of the alpha synuclein promoter in females with anorexia nervosa | Q95790350 | ||
| Parkin, PINK1, and DJ-1 form a ubiquitin E3 ligase complex promoting unfolded protein degradation | Q24312713 | ||
| Parkin is recruited selectively to impaired mitochondria and promotes their autophagy | Q24317471 | ||
| Hereditary early-onset Parkinson's disease caused by mutations in PINK1 | Q24337084 | ||
| Park7, a novel locus for autosomal recessive early-onset parkinsonism, on chromosome 1p36. | Q24535854 | ||
| Genome-wide association study confirms SNPs in SNCA and the MAPT region as common risk factors for Parkinson disease | Q24596763 | ||
| Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies | Q24606055 | ||
| Post-transcriptional regulation of alpha-synuclein expression by mir-7 and mir-153 | Q24633965 | ||
| Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. | Q24634577 | ||
| Genome-wide association study reveals genetic risk underlying Parkinson's disease | Q24646654 | ||
| Mutations in the GIGYF2 (TNRC15) gene at the PARK11 locus in familial Parkinson disease | Q24656075 | ||
| Kufor-Rakeb syndrome, pallido-pyramidal degeneration with supranuclear upgaze paresis and dementia, maps to 1p36 | Q24680678 | ||
| Mutation in the alpha-synuclein gene identified in families with Parkinson's disease | Q27860459 | ||
| alpha-Synuclein locus triplication causes Parkinson's disease | Q27860533 | ||
| GIGYF2 is present in endosomal compartments in the mammalian brains and enhances IGF-1-induced ERK1/2 activation | Q28116164 | ||
| Hereditary parkinsonism with dementia is caused by mutations in ATP13A2, encoding a lysosomal type 5 P-type ATPase | Q28116395 | ||
| The complex language of chromatin regulation during transcription | Q28131748 | ||
| Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 | ||
| Loss of function mutations in the gene encoding Omi/HtrA2 in Parkinson's disease | Q28257086 | ||
| Aggresome formation and neurodegenerative diseases: therapeutic implications | Q28265926 | ||
| Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 | ||
| FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome | Q28302099 | ||
| Sirtuin 2 inhibitors rescue alpha-synuclein-mediated toxicity in models of Parkinson's disease | Q28307422 | ||
| alpha-Synuclein produces a long-lasting increase in neurotransmitter release | Q28510893 | ||
| A MicroRNA feedback circuit in midbrain dopamine neurons | Q28513149 | ||
| α-Synuclein negatively regulates protein kinase Cδ expression to suppress apoptosis in dopaminergic neurons by reducing p300 histone acetyltransferase activity | Q28572683 | ||
| Mice lacking alpha-synuclein display functional deficits in the nigrostriatal dopamine system | Q28594502 | ||
| Comprehensive research synopsis and systematic meta-analyses in Parkinson's disease genetics: The PDGene database | Q29417106 | ||
| Repression of alpha-synuclein expression and toxicity by microRNA-7. | Q29542272 | ||
| The new mutation, E46K, of alpha-synuclein causes Parkinson and Lewy body dementia | Q29547174 | ||
| Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease | Q29547175 | ||
| Alpha-synuclein locus duplication as a cause of familial Parkinson's disease | Q29614762 | ||
| Genome-wide association study identifies common variants at four loci as genetic risk factors for Parkinson's disease | Q29614900 | ||
| The PINK1/Parkin pathway regulates mitochondrial morphology | Q29615641 | ||
| The Parkinson's disease genes pink1 and parkin promote mitochondrial fission and/or inhibit fusion in Drosophila | Q29617091 | ||
| Genomewide association study for susceptibility genes contributing to familial Parkinson disease | Q30437480 | ||
| POLG1-related and other "mitochondrial Parkinsonisms": an overview. | Q37827400 | ||
| Polyglutamine diseases: the special case of ataxin-3 and Machado-Joseph disease | Q37899333 | ||
| Genetic mutations and functions of PINK1. | Q37904442 | ||
| Identification of gene expression changes in transgenic C. elegans overexpressing human alpha-synuclein | Q38518569 | ||
| MicroRNA profiling of Parkinson's disease brains identifies early downregulation of miR-34b/c which modulate mitochondrial function | Q39545068 | ||
| Protection of dopaminergic cells from MPP+-mediated toxicity by histone deacetylase inhibition | Q39676713 | ||
| Allelic imbalance of expression and epigenetic regulation within the alpha-synuclein wild-type and p.Ala53Thr alleles in Parkinson disease. | Q39722408 | ||
| Parkin protects mitochondrial genome integrity and supports mitochondrial DNA repair | Q39823278 | ||
| Epigenetic identification of ubiquitin carboxyl-terminal hydrolase L1 as a functional tumor suppressor and biomarker for hepatocellular carcinoma and other digestive tumors. | Q39955983 | ||
| CpG hypermethylation of the UCHL1 gene promoter is associated with pathogenesis and poor prognosis in renal cell carcinoma | Q39979336 | ||
| Lrrk2 G2385R is an ancestral risk factor for Parkinson's disease in Asia | Q40251831 | ||
| Distinct effects on gene expression of chemical and genetic manipulation of the cancer epigenome revealed by a multimodality approach. | Q40503405 | ||
| Tau and alpha-synuclein in susceptibility to, and dementia in, Parkinson's disease | Q42628290 | ||
| Clinical spectrum of Kufor-Rakeb syndrome in the Chilean kindred with ATP13A2 mutations | Q42947297 | ||
| DJ-1 mutations are a rare cause of recessively inherited early onset parkinsonism mediated by loss of protein function | Q43073853 | ||
| Global microRNA expression profiling of Caenorhabditis elegans Parkinson's disease models | Q43187683 | ||
| Methylation status and neurodegenerative markers in Parkinson disease | Q43292322 | ||
| Association between anorexia nervosa and the hsKCa3 gene: a family-based and case control study. | Q43861801 | ||
| Gaucher disease with parkinsonian manifestations: does glucocerebrosidase deficiency contribute to a vulnerability to parkinsonism? | Q44479792 | ||
| The parkinsonian phenotype of spinocerebellar ataxia type 3 in a Taiwanese family | Q44984888 | ||
| DNA hypermethylation of the alpha synuclein promoter in patients with alcoholism | Q45239060 | ||
| Valproic acid is neuroprotective in the rotenone rat model of Parkinson's disease: involvement of alpha-synuclein. | Q45922508 | ||
| Nuclear localization of alpha-synuclein and its interaction with histones | Q46597702 | ||
| ??? | Q64786027 | ||
| Association analysis of MAPT H1 haplotype and subhaplotypes in Parkinson's disease | Q30493604 | ||
| Replication of MAPT and SNCA, but not PARK16-18, as susceptibility genes for Parkinson's disease. | Q30499875 | ||
| Elevated alpha-synuclein mRNA levels in individual UV-laser-microdissected dopaminergic substantia nigra neurons in idiopathic Parkinson's disease | Q33323265 | ||
| CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease | Q33760744 | ||
| Environmental neurotoxic pesticide increases histone acetylation to promote apoptosis in dopaminergic neuronal cells: relevance to epigenetic mechanisms of neurodegeneration | Q33762517 | ||
| Drosophila histone deacetylase 6 protects dopaminergic neurons against {alpha}-synuclein toxicity by promoting inclusion formation | Q33948478 | ||
| One-carbon metabolism and Alzheimer's disease: focus on epigenetics | Q34094250 | ||
| FGF20 rs12720208 SNP and microRNA-433 variation: no association with Parkinson's disease in Spanish patients. | Q34115520 | ||
| The UCH-L1 gene encodes two opposing enzymatic activities that affect alpha-synuclein degradation and Parkinson's disease susceptibility | Q34157005 | ||
| Regulation of intracellular manganese homeostasis by Kufor-Rakeb syndrome-associated ATP13A2 protein | Q34197130 | ||
| Parkin genetics: one model for Parkinson's disease | Q34300017 | ||
| DJ-1 acts in parallel to the PINK1/parkin pathway to control mitochondrial function and autophagy | Q34399382 | ||
| Abnormal methylation of the common PARK2 and PACRG promoter is associated with downregulation of gene expression in acute lymphoblastic leukemia and chronic myeloid leukemia | Q34467458 | ||
| Methylation regulates alpha-synuclein expression and is decreased in Parkinson's disease patients' brains. | Q34660005 | ||
| Alpha-synuclein sequesters Dnmt1 from the nucleus: a novel mechanism for epigenetic alterations in Lewy body diseases | Q34685028 | ||
| Molecular insights into Parkinson's disease | Q34988753 | ||
| Protective effects of valproic acid on the nigrostriatal dopamine system in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease | Q35385117 | ||
| Epigenetic mechanisms in developmental programming of adult disease. | Q35581063 | ||
| Suberoylanilide hydroxamic acid, a histone deacetylase inhibitor, protects dopaminergic neurons from neurotoxin-induced damage | Q35708210 | ||
| Advances in epigenetics and epigenomics for neurodegenerative diseases | Q35709124 | ||
| Exploring the link between glucocerebrosidase mutations and parkinsonism | Q35955350 | ||
| Paraquat induces epigenetic changes by promoting histone acetylation in cell culture models of dopaminergic degeneration | Q36123405 | ||
| The role of glucocerebrosidase mutations in Parkinson disease and Lewy body disorders | Q36486264 | ||
| Variation in the miRNA-433 binding site of FGF20 confers risk for Parkinson disease by overexpression of alpha-synuclein | Q36718966 | ||
| Genome-wide linkage analysis of a Parkinsonian-pyramidal syndrome pedigree by 500 K SNP arrays | Q36719174 | ||
| Biomarkers of folate and vitamin B(12) status in cerebrospinal fluid | Q36950520 | ||
| Spinocerebellar ataxia 2 (SCA2). | Q37140787 | ||
| Genetics, environmental factors and the emerging role of epigenetics in neurodegenerative diseases | Q37332243 | ||
| Parkin selectively alters the intrinsic threshold for mitochondrial cytochrome c release | Q37397403 | ||
| Histone deacetylases as targets for the treatment of human neurodegenerative diseases | Q37602632 | ||
| Epigenetic regulation in the pathophysiology of Alzheimer's disease | Q37680418 | ||
| Early-onset L-dopa-responsive parkinsonism with pyramidal signs due to ATP13A2, PLA2G6, FBXO7 and spatacsin mutations | Q37776461 | ||
| Epigenetics in neurodegeneration: a new layer of complexity. | Q37782161 | ||
| Genetic Analysis of Pathways to Parkinson Disease | Q37801078 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Parkinson's disease | Q11085 |
| P304 | page(s) | 489830 | |
| P577 | publication date | 2012-05-01 | |
| P1433 | published in | The Scientific World Journal | Q7762585 |
| P1476 | title | Genetics and epigenetics of Parkinson's disease. | |
| P478 | volume | 2012 |
| Q58556450 | A Comprehensive Analysis of the Association Between Polymorphisms and the Risk of Parkinson's Disease |
| Q37323166 | A review of quality of life after predictive testing for and earlier identification of neurodegenerative diseases |
| Q54112963 | Acetylome in Human Fibroblasts From Parkinson's Disease Patients. |
| Q39355888 | Acute exposure to a Mn/Zn ethylene-bis-dithiocarbamate fungicide leads to mitochondrial dysfunction and increased reactive oxygen species production in Caenorhabditis elegans |
| Q54159456 | Alpha-synuclein A53T mutation is not frequent on a sample of Brazilian Parkinson's disease patients. |
| Q52641621 | An Ontology Systems Approach on Human Brain Expression and Metaproteomics. |
| Q34992975 | Analysis of Thr12Met and Ala1144Thr mutations of the ATP13A2 gene in Parkinson's disease patients in Xinjiang Uygur and Han ethnic groups |
| Q38076411 | Cerebrospinal fluid biomarker candidates for parkinsonian disorders |
| Q38214427 | Circulating miRNAs as biomarkers for neurodegenerative disorders. |
| Q48713195 | Circulating microRNAs in Neurodegenerative Diseases. |
| Q26774368 | Computational Modelling Approaches on Epigenetic Factors in Neurodegenerative and Autoimmune Diseases and Their Mechanistic Analysis |
| Q58693508 | Epigenetic Study in Parkinson's Disease: A Pilot Analysis of DNA Methylation in Candidate Genes in Brain |
| Q38379396 | Epigenetic mechanisms in neurological and neurodegenerative diseases |
| Q92905568 | Epigenetics and Neurological Disorders in ART |
| Q34585744 | Eryptosis as a marker of Parkinson's disease |
| Q42083792 | Excessive levels of nitric oxide in rat model of Parkinson's disease induced by rotenone |
| Q46283329 | Fifty-Hertz Magnetic Field Affects the Epigenetic Modulation of the miR-34b/c in Neuronal Cells |
| Q38095350 | Histochemical approaches to assess cell-to-cell transmission of misfolded proteins in neurodegenerative diseases. |
| Q64237569 | Identification of potential blood biomarkers for Parkinson's disease by gene expression and DNA methylation data integration analysis |
| Q38645698 | Implications of DNA Methylation in Parkinson's Disease. |
| Q50243204 | Increase in DNA methylation in patients with amyotrophic lateral sclerosis carriers of not fully penetrant SOD1 mutations |
| Q38542025 | Integrative biomarker discovery in neurodegenerative diseases |
| Q33561039 | LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease |
| Q36128123 | Meta-Analysis of Parkinson's Disease Transcriptome Data Using TRAM Software: Whole Substantia Nigra Tissue and Single Dopamine Neuron Differential Gene Expression. |
| Q34100399 | Mutations in the ATP13A2 gene and Parkinsonism: a preliminary review |
| Q26859224 | Neuronal dark matter: the emerging role of microRNAs in neurodegeneration |
| Q61875301 | Paraquat: Molecular Mechanisms of Neurotoxicity and its Relation with Autophagy |
| Q37729129 | Parkinson's Disease: From Pathogenesis to Pharmacogenomics |
| Q58555658 | Pharmacoepigenomic Interventions as Novel Potential Treatments for Alzheimer's and Parkinson's Diseases |
| Q28088705 | Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes |
| Q45397285 | Physical activity in the prevention of human diseases: role of epigenetic modifications. |
| Q36851676 | Quantitation of hydrogen peroxide fluctuations and their modulation of dopamine dynamics in the rat dorsal striatum using fast-scan cyclic voltammetry |
| Q55004951 | Regulation of MicroRNAs-Mediated Autophagic Flux: A New Regulatory Avenue for Neurodegenerative Diseases With Focus on Prion Diseases. |
| Q90417635 | Role of viruses, prions and miRNA in neurodegenerative disorders and dementia |
| Q26744483 | Roles of PTEN with DNA Repair in Parkinson's Disease |
| Q56381130 | Sex-Specific Transcriptome Differences in Substantia Nigra Tissue: A Meta-Analysis of Parkinson's Disease Data |
| Q58051863 | Stratifying Heterogeneous Dimension of Neurodegenerative Diseases: Intervention for Stipulating Epigenetic Factors to Combat Oxidative Stress in Human Brain |
| Q38584755 | Targeting MicroRNAs in Prevention and Treatment of Neurodegenerative Disorders. |
| Q46624520 | The Emerging Role of MitomiRs in the Pathophysiology of Human Disease |
| Q42355152 | The effects of the novel A53E alpha-synuclein mutation on its oligomerization and aggregation. |
| Q64940430 | The epigenetics changes in Parkinson's disease: a novel therapeutic target. |
| Q38527233 | The epigenetics of aging and neurodegeneration. |
| Q38234971 | The potential of epigenetic therapies in neurodegenerative diseases |
| Q35631468 | Therapeutic perspectives of epigenetically active nutrients. |
| Q39273083 | Transcriptome Profile Changes in Mice with MPTP-Induced Early Stages of Parkinson's Disease |
| Q92824874 | VCP expression decrease as a biomarker of preclinical and early clinical stages of Parkinson's disease |
| Q46252338 | Vertebrate food products as a potential source of prion-like α-synuclein. |
Search more.